Rosacea — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for rosacea. 94 active patents protecting 7 drugs from 6+ originators. First major cliff: 2029. Daily refresh.

7
Approved drugs
94
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Rosacea

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 32 patents Generic (originally Merck/Upjohn) 29 patents Senju Pharmaceutical Co., Ltd 18 patents Baxter 9 patents Leo Pharma As 4 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating rosacea. Each bar = one year. Y-axis scaled to peak year (34 patents).

5
27
5
28
4
29
10
30
7
31
9
32
34
33
7
34
3
36
3
37
3
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lotemax
LOTEPREDNOL ETABONATE
 Bausch Health 32 42 — 2033-05-03
Alphagan
BRIMONIDINE TARTRATE
 Senju Pharmaceutical Co., Ltd 18 69 — 2029-07-27
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Metro I.V. In Plastic Container
METRONIDAZOLE
 Baxter 9 58 — 2028-02-02
Azelex
AZELAIC ACID
 Leo Pharma As 4 65 — 2027-09-18
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11596600 Alphagan method of use 81 2029-07-27
8455494 Alphagan method of use 81 2030-05-24
9259425 Alphagan method of use 81 2030-07-14
8293742 Alphagan method of use 81 2030-07-14
11833245 Alphagan method of use 76 2029-07-27
11596600 Alphagan method of use 76 2029-07-27
10117812 Azelex method of use 75 2027-10-18
8658678 Metro I.V. In Plastic Container method of use 75 2028-06-27
8869794 Tobi method of use 75 2028-09-12
9211259 Azelex method of use 75 2029-02-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10688045 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
10646436 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
10646437 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14

Related